KRAS and cancer: Activating mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) gene are one of the most common oncogenic driver mutations in human cancers, including non-small cell lung cancer (NSCLC), where they account for about 30% of lung adenocarcinomas in western countries and 10% in Asian countries1.